Claudia’s Story: Clearity Changed My Journey

November 26, 2019 6:00 am

Like many women, Claudia knew something wasn’t quite right when she began to experience an unusual pain in her pelvic area and excessive sweating while at work. Later in the night, she ended up in the hospital with emergency surgery, … Read more

The Important Lessons Learned from Cancer Caregivers

November 22, 2019 12:00 pm

This article shares important lessons for caregivers, on how to not only support their loved one, but themselves. At The Clearity Foundation, we provide support to women with ovarian cancer and their families. We understand that while taking care Read more

Barbara’s Story: Clearity Can Be our Home Away from Home

November 19, 2019 6:00 am

My name is Barbara Sanders. I’m 65 years old and live in San Diego, California. Today I enjoy all America’s Finest City has to offer including long hikes year-round, reading on the beach and boating with friends. But life wasn’t … Read more

Second Surgery for Many Ovarian Cancers Found Ineffective

November 14, 2019 5:00 pm

By Gene Emery

Going back into the operating room for surgery to help a woman whose ovarian cancer has reappeared may not help her live longer – instead, it might shorten her life, according to an international study of 485 … Read more

Alexis’ Story: Live Your Best Life

November 12, 2019 8:00 am

When I was a teenager, I found out that I had Polycystic ovary syndrome (PCOS). PCOS is a hormonal disorder that can cause cysts on the ovaries, and I would often feel when I had cysts, and when they would … Read more

Steps Through OC Awarded the 2019 AONN+ Outstanding Poster Award for Exceptional Research in Navigation

November 7, 2019 5:00 pm

Photo: Marina Baroff, MPH, FACHE, Senior Director, Service Innovation
mbaroff@stepsthrough.org | www.stepsthrough.org

The Clearity Foundation is proud to announce that our new support program, Steps Through OC, has been selected for the 2019 AONN+ Outstanding Poster Award for Exceptional Read more

CA125 Test Detects Far More Ovarian Cancer Cases Than Thought

November 6, 2019 6:00 pm

By Liam Davenport

A blood test for detecting ovarian cancer is far more effective in the primary care setting than previously thought, say UK researchers, who suggest National Institute for Health and Care Excellence (NICE) guidelines will need to be … Read more

Queency’s Story: Ovarian Cancer Never Crossed My Mind

November 5, 2019 8:00 am

When I was first diagnosed with ovarian cancer, I made the decision to share my story, not because it was glamorous, but in the hope that I could save a life. In February of 2018, after missing my period, I

Read more

Say Something To Your Friend With Cancer

October 26, 2019 4:00 pm

By Martha Carlson

A single question acknowledging someone else’s experience can lift the heavy feeling of cancer isolation.

I’ve written before that, for me at least, there are really only two things that need to be said to someone with … Read more

Genetically Definable Subgroups of Cancers Sensitive to Treatment

October 24, 2019 5:00 pm

Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more

FDA Approves Zejula for Advanced Ovarian Cancer Subset

October 23, 2019 3:30 pm

By Jessica Skarzynski

The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous Read more

Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

‘Wild Idea’ Opens Possible New Frontier for Preventing Ovarian Cancer

October 9, 2019 3:00 pm

A laboratory study published in Clinical Cancer Research offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.

The study is the first to show that the natural stiffening of the ovaries called fibrosis … Read more

How Has Cancer Changed the Way Patients Live Their Lives?

October 5, 2019 5:00 pm

We would love to hear from the Clearity Community – patients, caregivers, and loved ones – about your experiences on how you have been affected by ovarian cancer. Sharing your story is a way to promote awareness, connect with people Read more

Searching for Cancer Information: Go Ahead and ‘Google It’

October 2, 2019 6:00 pm

With so much information at your fingertips, we understand how difficult it can be to find trustworthy, lay friendly sources that are relevant to you and your specific ovarian cancer journey. The Clearity Foundation exists to help women find credible Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more